Refractoriness of diabetic platelets to inhibitory prostaglandins.
Inhibition of collagen-induced platelet aggregation by either endothelial extracts, prostacyclin, prostaglandin E1 or prostaglandin D2 was investigated. The inhibition was less efficient with diabetic platelets than with platelets from normal donors. The refractoriness of diabetic platelets to inhibitory prostaglandins was observed both with platelet-rich plasma and platelets isolated from their plasma. Moreover levels of cyclic AMP in resting platelets and after stimulation by either PGE1 or PGD2 were lower in diabetic platelets than in normal platelets. It is concluded that the weaker response of diabetic platelets to inhibitory prostaglandins could be related to their content in cyclic AMP.
D000293:Adolescent; D000328:Adult; D000527:Alprostadil; D003094:Collagen / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood*; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000494:pharmacology*; D011457:Prostaglandins D / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology
D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D003094:Collagen; D011464:Epoprostenol; D000242:Cyclic AMP; D000527:Alprostadil; D015230:Prostaglandin D2